Aligos Therapeutics, Inc.
ALGS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001799448
No open-market purchases or sales by Aligos Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.2M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Q2 2023 vs. Q1 2023
How the institutions holding Aligos Therapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 46 | 41 | −5 |
| Shares | 27.3M | 26.3M | −1.00M (−3.7%) |
| Value | $23.9M | $25.5M | +$1.62M (+6.8%) |
New holders (3)
Institutions that held Aligos Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Charles Schwab Investment Management Inc | 31,383 | $30.5K | 0.00% |
| Choate Investment Advisors | 24,000 | $23.3K | 0.00% |
| Virtu Financial LLC | 18,353 | $18.0K | 0.00% |
Sold out (8)
Institutions that held Aligos Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Logos Global Management LP | 1,000,000 | $874.0K |
| Marshall Wace, LLP | 108,588 | $94.5K |
| Man Group plc | – | $49.5K |
| Jane Street Group, LLC | 26,249 | $22.9K |
| Susquehanna International Group, LLP | 24,594 | $21.5K |
| Cubist Systematic Strategies, LLC | 13,292 | $11.6K |
| Point72 Asset Management, L.P. | 247 | $216 |
| Tower Research Capital LLC (TRC) | 92 | $0 |